StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Trading Down 99.7 % NYSE NAVB opened at $0.00 on Thursday. The company has a 50 day moving average of $0.04 and […]